Human Islet Microtissues as an In Vitro and an In Vivo Model System for Diabetes

• Published in: International journal of molecular sciences 2021-02, Vol.22 (4), p.1813
• Main Authors: Mir-Coll, Joan, Moede, Tilo, Paschen, Meike, Neelakandhan, Aparna, Valladolid-Acebes, Ismael, Leibiger, Barbara, Biernath, Adelinn, Ämmälä, Carina, Leibiger, Ingo B, Yesildag, Burcak, Berggren, Per-Olof
• Format: Article
• Language: English
• Subjects: Animals; Diabetes Mellitus, Experimental - metabolism; Diabetes Mellitus, Experimental - pathology; Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - pathology; Heterografts; Humans; Insulin-Secreting Cells - metabolism; Insulin-Secreting Cells - pathology; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred NOD; Mice, Knockout
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22041813

Loss of pancreatic β-cell function is a critical event in the pathophysiology of type 2 diabetes. However, studies of its underlying mechanisms as well as the discovery of novel targets and therapies have been hindered due to limitations in available experimental models. In this study we exploited the stable viability and function of standardized human islet microtissues to develop a disease-relevant, scalable, and reproducible model of β-cell dysfunction by exposing them to long-term glucotoxicity and glucolipotoxicity. Moreover, by establishing a method for highly-efficient and homogeneous viral transduction, we were able to monitor the loss of functional β-cell mass in vivo by transplanting reporter human islet microtissues into the anterior chamber of the eye of immune-deficient mice exposed to a diabetogenic diet for 12 weeks. This newly developed in vitro model as well as the described in vivo methodology represent a new set of tools that will facilitate the study of β-cell failure in type 2 diabetes and would accelerate the discovery of novel therapeutic agents.